Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As pioneers in the procedure markets that we have developed, we believe RedPoint PSI is a core technology with capability to achieve broad market adoption in the years ahead, further strengthening our leadership position |
| We believe we have a lengthy runway in terms of our current cash level with sufficient balance sheet strength and flexibility to continue aggressively executing on our strategic investments and growth initiatives as well as a clear path to achieve positive adjusted EBITDA |
| We're excited about Nathan's expertise and the impact he's been able to have quickly on the business |
| 2023 was a busy and productive year for Treace, and we're proud of the significant progress that we've made |
| So, we know that given scale and higher revenue volumes that we're definitely poised to have that improvement in our bottom line in that adjusted EBITDA line |
| revenue growth of 32%, surpassing the high end of our previously provided guidance range and growth that we believe is significantly above our foot and ankle peers |
| We also continue to scale our operations, making encouraging adjusted EBITDA progress that was head of the prior year and delivering gains across our key operating metrics, reaffirming our belief that we have the right strategies in place to expand the market penetration of our differentiated technologies |
| with continued strong adoption by the foot and ankle surgeon community and with nearly 1 in 4 adults in the U.S |
| affected by bunions, we believe this represents the most compelling opportunity in the foot and ankle reconstructive market today |
| As we mentioned in the prepared remarks we had positive EBITDA in the fourth quarter |
| And we've proven that we can establish a powerful direct channel that's really well sustaining with room for future year nice cost leverage as well |
| It's been off to a really good start, we've heard very positive feedback on it |
| And I guess from 2 perspectives, one, when you're giving us this guide, what was your mindset? I mean, I could argue that the market seems strong, the sales force is doing a good job, you're clearly training the physicians, the portfolio is expanding, the SpeedPlate launched and demand seems incredibly strong, you get the picture |
| We expect all of these new technologies to fuel strong growth for years to come |
| As a uniquely focused foot and ankle company, we believe we're distinctly positioned to drive innovation-led growth and deliver long-term shareholder value |
| We believe we're in a great position strategically with best-in-class bunion, midfoot and related complementary offerings and expanding TAM with the addition of new technologies such as Adductoplasty, hammertoe and SpeedPlate with more innovations to come, supported by differentiating clinical studies, continued strong additions to our surgeon base and a powerful and established direct sales team |
| Along the way, we've also taken bold steps to grow and defend the markets we pioneered through our direct sales team, rapid product innovation and our patient awareness and education initiatives, all of which we believe have resulted in a sizable competitive advantage for Treace |
| In closing, we delivered another year of significant progress in 2023 and expect to remain on track to drive strong growth and profitably scale our business in the years ahead |
| These new surgeon additions and training our large active surgeon base on new procedures is expected to expand utilization and drive blended ASP increases |
| These results demonstrate the underlying strength and effectiveness of our strategic investments in our direct sales channel, targeted R&D initiatives and direct-to-consumer programs |
| Fourth quarter was also our first quarter of positive adjusted EBITDA since going public in April of 2021 |
| We continue to advance our key performance metrics in the fourth quarter, including substantial gains in the number of new surgeon users ending Q4 with 2,855 active surgeons, up 164 for the quarter and up 20% year-over-year |
| While these are great offensive tools, they position us with a very strong defense as well and we're just going to keep reinforcing that over time and continuing to grow and establish ourselves as the fastest-growing company in the foot and ankle market, which is what we are today and where we're going to continue to be |
| Our strategic investments and commercial focus have continued to support the growth of our business, giving us confidence that we have a well-defined, proven and scalable commercial strategy |
| So, we feel good about the sales team, we feel good about their capacity to bring these other technologies forward and part of it is because of the efficiency of this model and the way we're bringing these products out |
| We expect to make significant improvement in adjusted EBITDA for the full year 2024 and anticipate adjusted EBITDA to improve approximately 50% compared to full year 2023 |
| As I mentioned earlier, we saw strong growth in our active surgeon base in Q4 and for the full year |
| As our surgeon base continues to develop and gain tenure, we anticipate utilization gains with increased use of Lapiplasty and Adductoplasty as well as further adoption of our growing portfolio of complementary products, all supported by our expanding direct sales channel, differentiating clinical data sets and patient education and awareness DTC initiatives |
| Our SpeedPlate launch is off to a great start, and we saw a very strong demand in the fourth quarter despite its limited availability |
| We remain encouraged by the underlying strength and momentum in our business with our strategic investments clearly delivering on growth |
| Statement |
|---|
| For the full year 2023 gross margin was 81.2%, down from 82% in the prior year period, primarily due to changes in product mix and increase in inventory provisions and an increase in overhead costs due to head count to support the growing business, partially offset by lower royalty rates |
| Given a lot of new product launches and some of the mix shift we're anticipating maybe the gross margin to come down a little bit and we've talked about this in the past, as we introduce new products, we just don't quite have the same efficiencies in the gross margin initially |
| And so, I view 2024 as having maybe some slight pressure on the gross margin but nothing substantial |
| Just should we think of gross margin in the first half a little bit below what is going to be in the second half and on a net basis for the full year, it's down? I mean just to get the cadence right |
| Hi, Rich, so, I think there's a little bit of confusion out there on this topic because I know there's a lot of contemporary discussion about hip and knee volumes moving to the ASC setting, that outpatient setting |
| But the one thing that we see right now is, you talked about 32% for the full year, but the last 2 quarters, third quarter and fourth quarter were a little bit below that |
| And admittedly, even with the seasonality, it leads more of a back half-loaded guide but it's very early still, and we don't see it representing any loss of our momentum going into 2024 |
| Consistent with previous years, we expect a sequential revenue decrease from Q4 to Q1 due to normal seasonality coming off our usual strong year-end performance |
| And then you have to keep in mind these new entrants are entering the market using multiline, largely distracted sales forces |
| We tend to have larger losses earlier in the year as we begin some of our marketing programs early in the year, some of our medical education programs that we start early in Q1 and Q2 |
| Fourth quarter net loss was $6.3 million or $0.10 per share compared to a net loss of $4.4 million or $0.08 per share for the same period of 2022 |
| With respect to gross margin, again, we're not expecting substantial decreases over 2023, but I think the way you articulated it is the way we're thinking about it, that earlier in the year, it may be a little bit lower with some improvement in the back half of next year |
| I just wanted to say that it will be tempered slightly versus last year |
| So, again, just a slight step down year-over-year |
| Why shouldn't we expect you to be more optimistic |
Please consider a small donation if you think this website provides you with relevant information